Mismatch Repair and Treatment Resistance in Ovarian Cancer
Author Information
Author(s): Helleman Jozien, van Staveren Iris L, Dinjens Winand NM, van Kuijk Patricia F, Ritstier Kirsten, Ewing Patricia C, van der Burg Maria EL, Stoter Gerrit, Berns Els MJJ
Primary Institution: Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Hypothesis
What is the frequency of mismatch repair (MMR) inactivation in ovarian cancer, and is it associated with platinum-based chemotherapy resistance?
Conclusion
No MMR inactivation was detected in 75 ovarian carcinoma specimens, and no association was seen between MMR inactivation and resistance in the ovarian cancer cell lines as well as the ovarian carcinomas.
Supporting Evidence
- MSI was detected in three of the eight cell lines.
- Seven of the 75 ovarian carcinomas showed MLH1 promoter methylation.
- Overall, there was no association between cisplatin response and MMR status in these eight cell lines.
- None of the ovarian carcinomas showed MSI for BAT25, BAT26, and for BAT40 or D2S123.
Takeaway
The study looked at ovarian cancer to see if a certain type of DNA repair problem made the cancer harder to treat. They found that this problem wasn't linked to treatment resistance.
Methodology
The study analyzed 75 ovarian carcinomas and eight ovarian cancer cell lines for microsatellite instability (MSI) and MLH1 promoter methylation status.
Limitations
The study's findings may not be generalizable due to the specific patient population and the limited number of specimens analyzed.
Participant Demographics
Median age of participants was 52 years, with a range from 27 to 83 years.
Statistical Information
P-Value
p = 0.664
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website